vs
CASTLE BIOSCIENCES INC（CSTL）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
PREFORMED LINE PRODUCTS CO的季度营收约是CASTLE BIOSCIENCES INC的2.0倍（$173.1M vs $87.0M），PREFORMED LINE PRODUCTS CO同比增速更快（3.6% vs 0.8%），CASTLE BIOSCIENCES INC自由现金流更多（$19.7M vs $11.8M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 9.2%）
Castle Biosciences是一家处于商业阶段的诊断企业，专注于开发和商业化针对黑色素瘤等皮肤癌及罕见病的专利临床诊断检测产品，主要服务美国医疗市场，聚焦未被满足的精准诊断需求领域，辅助临床医生制定治疗决策。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
CSTL vs PLPC — 直观对比
营收规模更大
PLPC
是对方的2.0倍
$87.0M
营收增速更快
PLPC
高出2.8%
0.8%
自由现金流更多
CSTL
多$8.0M
$11.8M
两年增速更快
PLPC
近两年复合增速
9.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $87.0M | $173.1M |
| 净利润 | — | $8.4M |
| 毛利率 | 79.0% | 29.8% |
| 营业利润率 | -4.4% | 6.8% |
| 净利率 | — | 4.9% |
| 营收同比 | 0.8% | 3.6% |
| 净利润同比 | — | -19.3% |
| 每股收益（稀释后） | $-0.06 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTLPLPC
| Q4 25 | $87.0M | $173.1M | ||
| Q3 25 | $83.0M | $178.1M | ||
| Q2 25 | $86.2M | $169.6M | ||
| Q1 25 | $88.0M | $148.5M | ||
| Q4 24 | $86.3M | $167.1M | ||
| Q3 24 | $85.8M | $147.0M | ||
| Q2 24 | $87.0M | $138.7M | ||
| Q1 24 | $73.0M | $140.9M |
净利润CSTLPLPC
| Q4 25 | — | $8.4M | ||
| Q3 25 | $-501.0K | $2.6M | ||
| Q2 25 | $4.5M | $12.7M | ||
| Q1 25 | $-25.8M | $11.5M | ||
| Q4 24 | — | $10.5M | ||
| Q3 24 | $2.3M | $7.7M | ||
| Q2 24 | $8.9M | $9.4M | ||
| Q1 24 | $-2.5M | $9.6M |
毛利率CSTLPLPC
| Q4 25 | 79.0% | 29.8% | ||
| Q3 25 | 77.5% | 29.7% | ||
| Q2 25 | 79.5% | 32.7% | ||
| Q1 25 | 81.4% | 32.8% | ||
| Q4 24 | 81.3% | 33.3% | ||
| Q3 24 | 81.8% | 31.1% | ||
| Q2 24 | 83.3% | 31.9% | ||
| Q1 24 | 81.0% | 31.3% |
营业利润率CSTLPLPC
| Q4 25 | -4.4% | 6.8% | ||
| Q3 25 | -8.2% | 7.4% | ||
| Q2 25 | -4.9% | 10.1% | ||
| Q1 25 | -31.7% | 8.8% | ||
| Q4 24 | 4.7% | 10.5% | ||
| Q3 24 | 5.9% | 7.1% | ||
| Q2 24 | 5.8% | 8.1% | ||
| Q1 24 | -7.5% | 8.2% |
净利率CSTLPLPC
| Q4 25 | — | 4.9% | ||
| Q3 25 | -0.6% | 1.5% | ||
| Q2 25 | 5.2% | 7.5% | ||
| Q1 25 | -29.4% | 7.8% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | 2.6% | 5.2% | ||
| Q2 24 | 10.3% | 6.8% | ||
| Q1 24 | -3.5% | 6.8% |
每股收益（稀释后）CSTLPLPC
| Q4 25 | $-0.06 | $1.72 | ||
| Q3 25 | $-0.02 | $0.53 | ||
| Q2 25 | $0.15 | $2.56 | ||
| Q1 25 | $-0.90 | $2.33 | ||
| Q4 24 | $0.32 | $2.13 | ||
| Q3 24 | $0.08 | $1.54 | ||
| Q2 24 | $0.31 | $1.89 | ||
| Q1 24 | $-0.09 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.5M | — |
| 总债务越低越好 | $10.1M | $38.3M |
| 股东权益账面价值 | $470.9M | $475.5M |
| 总资产 | $578.6M | $653.6M |
| 负债/权益比越低杠杆越低 | 0.02× | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资CSTLPLPC
| Q4 25 | $299.5M | — | ||
| Q3 25 | $287.5M | — | ||
| Q2 25 | $275.9M | — | ||
| Q1 25 | $275.2M | — | ||
| Q4 24 | $293.1M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $85.6M | — | ||
| Q1 24 | $82.9M | — |
总债务CSTLPLPC
| Q4 25 | $10.1M | $38.3M | ||
| Q3 25 | $10.0M | $36.0M | ||
| Q2 25 | $10.0M | $31.8M | ||
| Q1 25 | $10.0M | $29.1M | ||
| Q4 24 | $10.0M | $20.8M | ||
| Q3 24 | $10.0M | $27.2M | ||
| Q2 24 | $10.0M | $31.6M | ||
| Q1 24 | $10.0M | $55.0M |
股东权益CSTLPLPC
| Q4 25 | $470.9M | $475.5M | ||
| Q3 25 | $467.0M | $466.3M | ||
| Q2 25 | $455.4M | $460.7M | ||
| Q1 25 | $440.3M | $435.8M | ||
| Q4 24 | $455.8M | $422.3M | ||
| Q3 24 | $441.1M | $429.0M | ||
| Q2 24 | $423.9M | $416.2M | ||
| Q1 24 | $402.5M | $413.4M |
总资产CSTLPLPC
| Q4 25 | $578.6M | $653.6M | ||
| Q3 25 | $562.8M | $644.6M | ||
| Q2 25 | $544.7M | $631.5M | ||
| Q1 25 | $501.7M | $592.5M | ||
| Q4 24 | $531.2M | $573.9M | ||
| Q3 24 | $514.6M | $592.0M | ||
| Q2 24 | $487.3M | $572.6M | ||
| Q1 24 | $458.5M | $586.1M |
负债/权益比CSTLPLPC
| Q4 25 | 0.02× | 0.08× | ||
| Q3 25 | 0.02× | 0.08× | ||
| Q2 25 | 0.02× | 0.07× | ||
| Q1 25 | 0.02× | 0.07× | ||
| Q4 24 | 0.02× | 0.05× | ||
| Q3 24 | 0.02× | 0.06× | ||
| Q2 24 | 0.02× | 0.08× | ||
| Q1 24 | 0.02× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.9M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $19.7M | $11.8M |
| 自由现金流率自由现金流/营收 | 22.7% | 6.8% |
| 资本支出强度资本支出/营收 | 8.3% | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.60× |
| 过去12个月自由现金流最近4个季度 | $28.3M | $33.3M |
8季度趋势，按日历期对齐
经营现金流CSTLPLPC
| Q4 25 | $26.9M | $21.9M | ||
| Q3 25 | $22.6M | $18.9M | ||
| Q2 25 | $20.8M | $26.9M | ||
| Q1 25 | $-6.0M | $5.7M | ||
| Q4 24 | $24.4M | $24.1M | ||
| Q3 24 | $23.3M | $9.4M | ||
| Q2 24 | $24.0M | $28.3M | ||
| Q1 24 | $-6.8M | $5.8M |
自由现金流CSTLPLPC
| Q4 25 | $19.7M | $11.8M | ||
| Q3 25 | $7.8M | $8.3M | ||
| Q2 25 | $11.6M | $18.6M | ||
| Q1 25 | $-10.8M | $-5.3M | ||
| Q4 24 | $16.8M | $20.6M | ||
| Q3 24 | $17.0M | $5.8M | ||
| Q2 24 | $18.8M | $24.6M | ||
| Q1 24 | $-16.0M | $1.8M |
自由现金流率CSTLPLPC
| Q4 25 | 22.7% | 6.8% | ||
| Q3 25 | 9.4% | 4.7% | ||
| Q2 25 | 13.4% | 10.9% | ||
| Q1 25 | -12.2% | -3.6% | ||
| Q4 24 | 19.5% | 12.3% | ||
| Q3 24 | 19.8% | 3.9% | ||
| Q2 24 | 21.6% | 17.7% | ||
| Q1 24 | -21.9% | 1.3% |
资本支出强度CSTLPLPC
| Q4 25 | 8.3% | 5.9% | ||
| Q3 25 | 17.9% | 6.0% | ||
| Q2 25 | 10.7% | 4.9% | ||
| Q1 25 | 5.4% | 7.4% | ||
| Q4 24 | 8.8% | 2.1% | ||
| Q3 24 | 7.4% | 2.4% | ||
| Q2 24 | 6.0% | 2.7% | ||
| Q1 24 | 12.5% | 2.8% |
现金转化率CSTLPLPC
| Q4 25 | — | 2.60× | ||
| Q3 25 | — | 7.21× | ||
| Q2 25 | 4.60× | 2.12× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | 10.29× | 1.22× | ||
| Q2 24 | 2.69× | 3.02× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
PLPC
暂无分部数据
